Michael Shan
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Hepatitis C virus research
- Epidemiology top 5%
- Liver Disease Diagnosis and Treatment
- Urinary Tract Infections Management
- Hepatitis B Virus Studies
Papers in
-
- Renal cell carcinoma treatment 1
- Cystic Fibrosis Research Advances 1
-
- Pneumonia and Respiratory Infections 2
- Co-authors
- Jordi Bruix (2 shared papers)Josep M. Llovet (2 shared papers)Carol E. Peña (2 shared papers)Gerold Meinhardt (1 shared paper)Chetan Lathia (2 shared papers)Andrea Nadel (1 shared paper)D. Voliotis (1 shared paper)Luigi Bolondi (1 shared paper)
- Journals
- Molecular Cancer Therapeutics (1 paper)Clinical Infectious Diseases (1 paper)Clinical Cancer Research (1 paper)Journal of Hepatology (1 paper)The American Journal of Medicine (1 paper)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Michael Shan
9 papers receiving 1.4k citations
Michael Shan's Hit Papers
Peers
Comparison fields: 5 of 76
- Hepatology 811
- Epidemiology 396
- Cancer Research 167
- Pathology and Forensic Medicine 190
- Urology 58
Countries citing papers authored by Michael Shan
This map shows the geographic impact of Michael Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Shan more than expected).
Fields of papers citing papers by Michael Shan
This network shows the impact of papers produced by Michael Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Shan. The network helps show where Michael Shan may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Shan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial Hit paper breakdown → | 2012 | 675 |
| 2 | Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma Hit paper breakdown → | 2012 | 453 |
| 3 | 1999 | 133 | |
| 4 | 1998 | 64 | |
| 5 | 2007 | 30 | |
| 6 | 1999 | 26 | |
| 7 | 1999 | 25 | |
| 8 | 2001 | 13 | |
| 9 | 2009 | 2 |
About Michael Shan
Michael Shan is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology, Otorhinolaryngology, Hepatology and Surgery, having authored 9 papers that have together received 1.4k indexed citations. Recurring topics across this work include Sinusitis and nasal conditions (2 papers), Pneumonia and Respiratory Infections (2 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Renal cell carcinoma treatment (1 paper), Cancer Genomics and Diagnostics (1 paper), Cystic Fibrosis Research Advances (1 paper), Statistical Methods in Clinical Trials (1 paper) and Ear Surgery and Otitis Media (1 paper). The work is most often cited by research in Hepatology (811 citations), Epidemiology (396 citations), Cancer Research (167 citations), Pathology and Forensic Medicine (190 citations) and Urology (58 citations). Michael Shan has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Jordi Bruix, Josep M. Llovet, Carol E. Peña, Gerold Meinhardt, Chetan Lathia, Andrea Nadel, D. Voliotis, Luigi Bolondi, Vincenzo Mazzaferro and Morris Sherman. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Infectious Diseases, Clinical Cancer Research, Journal of Hepatology and The American Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.